182 related articles for article (PubMed ID: 22627739)
1. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
Gianelli U; Vener C; Bossi A; Cortinovis I; Iurlo A; Fracchiolla NS; Savi F; Moro A; Grifoni F; De Philippis C; Radice T; Bosari S; Lambertenghi Deliliers G; Cortelezzi A
Mod Pathol; 2012 Sep; 25(9):1193-202. PubMed ID: 22627739
[TBL] [Abstract][Full Text] [Related]
2. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.
Lekovic D; Gotic M; Perunicic-Jovanovic M; Vidovic A; Bogdanovic A; Jankovic G; Cokic V; Milic N
Med Oncol; 2014 Mar; 31(3):869. PubMed ID: 24500865
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.
Vener C; Fracchiolla NS; Gianelli U; Calori R; Radaelli F; Iurlo A; Caberlon S; Gerli G; Boiocchi L; Deliliers GL
Blood; 2008 Feb; 111(4):1862-5. PubMed ID: 18029552
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
[TBL] [Abstract][Full Text] [Related]
5. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
[TBL] [Abstract][Full Text] [Related]
6. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
Gianelli U; Fiori S; Cattaneo D; Bossi A; Cortinovis I; Bonometti A; Ercoli G; Bucelli C; Orofino N; Bulfamante G; Iurlo A
Histopathology; 2017 Dec; 71(6):897-908. PubMed ID: 28710830
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
9. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
10. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
11. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
[TBL] [Abstract][Full Text] [Related]
12. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
13. European consensus on grading bone marrow fibrosis and assessment of cellularity.
Thiele J; Kvasnicka HM; Facchetti F; Franco V; van der Walt J; Orazi A
Haematologica; 2005 Aug; 90(8):1128-32. PubMed ID: 16079113
[TBL] [Abstract][Full Text] [Related]
14. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
Curto-Garcia N; Ianotto JC; Harrison CN
Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
[TBL] [Abstract][Full Text] [Related]
15. Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
Masarova L; Bose P; Pemmaraju N; Daver NG; Sasaki K; Chifotides HT; Zhou L; Kantarjian HM; Estrov Z; Verstovsek S
Cancer; 2022 Apr; 128(8):1658-1665. PubMed ID: 35077575
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia.
Buesche G; Georgii A; Duensing A; Schmeil A; Schlue J; Kreipe HH
Hum Pathol; 2003 Apr; 34(4):391-401. PubMed ID: 12733122
[TBL] [Abstract][Full Text] [Related]
17. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
18. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes.
Buesche G; Teoman H; Wilczak W; Ganser A; Hecker H; Wilkens L; Göhring G; Schlegelberger B; Bock O; Georgii A; Kreipe H
Leukemia; 2008 Feb; 22(2):313-22. PubMed ID: 18033321
[TBL] [Abstract][Full Text] [Related]
19. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
20. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Cervantes F; Dupriez B; Pereira A; Passamonti F; Reilly JT; Morra E; Vannucchi AM; Mesa RA; Demory JL; Barosi G; Rumi E; Tefferi A
Blood; 2009 Mar; 113(13):2895-901. PubMed ID: 18988864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]